（以下内容从华福证券《医药生物行业HER3 ADC：有望首次成药，关注末线治疗潜力》研报附件原文摘录） 投资要点： 行情回顾：本本周（2025年2月24 ...

Now, a study by Chiu and colleagues reports that HER3 status is also an important prognostic marker of breast cancer-specific survival. ...HER3 expression was... significantly associated with ...

Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer: Tokyo Thursday, March 20, 2025, ...

Injectable AK138D1 is a HER3-targeted antibody-drug conjugate (ADC), with a fully humanized anti-HER3 IgG1 antibody, patritumab. It is conjugated to the topoisomerase I inhibitor DXd through a ...

Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer.

Injectable AK138D1 is a HER3-targeted antibody-drug conjugate (ADC), with a fully humanized anti-HER3 IgG1 antibody, patritumab. It is conjugated to the topoisomerase I inhibitor DXd through a ...